Short-term outcomes of extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus: a double-blind, randomized, placebo-controlled trial

Table 4 Comparison of shoulder ratings before and 3 months after ESWT/sham treatment in the study and placebo groups

CMS	ESWT	PLACEBO	P value¹
PAIN
Baseline	2.72 ± 2.61 (0-5)	3.33 ± 2.5 (0-5)	0.592
3 months	10.9 ± 4.37 (5-15)	6.11 ± 4.86 (0-15)	0.039
P value²	0.004	0.096
ADL
Baseline	10.27 ± 3.28 (5-18)	11.55 ± 4.21 (6-18)	0.378
3 months	17 ± 4.22 (8-20)	12 ± 5.63 (4-20)	0.059
P value²	0.005	0.779
ROM
Baseline	16.18 ± 4.68 (10-24)	16.67 ± 8.36 (2-26)	0.878
3 months	30.9 ± 9.05 (16-40)	18.22 ± 10.50 (6-36)	0.012
P value²	0.005	0.635
POWER
Baseline	13.27 ± 5.40 (5-20)	10.11 ± 3.18 (5-15)	0.170
3 months	15.27 ± 6 (6-23)	11.67 ± 3.46 (6-16)	0.170
P value²	0.096	0.119
TOTAL
Baseline	42.45 ± 9.83 (29-61)	41.67 ± 12.53 (20-57)	0.970
3 months	74.09 ± 20.56 (39-98)	48 ± 22.3 (17-79)	0.023
P value²	0.003	0.260

The values are given as mean ± standard deviation (range).
¹ Comparison between treatment and control group both before and after treatment (Mann-Whitney U- test).
² Comparison between before and after treatment within each group (Wilcoxon test).
ESWT, indicates extracorporeal shock wave therapy; ADL, activity of daily living; ROM, range of motion; CMS, Constant and Murley Score.

ISSN: 1471-2474